Company intelligence / Profile preview

Kangpu Biopharmaceuticals

Hefei, Anhui Province, Chinakangpugroup.com ↗

Ownership: Private
Employees: ~49
Development stage: Phase 2

Overview

KPG-818 has completed Phase IIa clinical trials for SLE in the US with promising preliminary efficacy in patients with cutaneous manifestations. It has received approval for Phase IIb trials for moderate to severe cutaneous manifestations of SLE in China. KPG-818 has also received IND approval for relapsed/refractory multiple myeloma treatment in China, with Phase I trials completed in the US showing good safety, tolerability, and encouraging therapeutic effects.

Therapeutic areas: RheumatologyOncologyImmunologyHematology
Modalities: Small moleculesDegradable Molecular GlueDegrader-antibody conjugates
Industry: Biotech

Drug pipeline

4 assets

epaldeudomide

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Kangpu Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kangpu Biopharmaceuticals.

Explore the full profile